Clinical Evidence of Skin Improvements With a Biologically Active Multimodal Topical Skin Treatment

September 2026 | Volume 25 | Issue 9 | 814 | Copyright © September 2026


Published online August 31, 2026

Zein E. Obagi MDa, Raffi J. Balian BS MSb, Susan V. Ramsey DRSc MS RACb, Frederick W. Woodin Jr. BS MAb, Grace H. Nguyen BAb

aZO Skin Centre, Beverly Hills, CA
bZO Skin Health, Inc., Irvine, CA

Abstract
Background: Antiaging skin treatments are continuously in development to meet the needs of an aging population and counteract cosmetic effects of glucagon-like peptide-1 receptor agonists. Peptide Facial Refining Concentrate (ST26-PF-F1) serum contains multiple bioactive peptides within a penetrative delivery system. A clinical study of ST26-PF-F1 assessed its effects on skin health/appearance and tolerability/usability.
Methods: This noncomparative 12-week study enrolled healthy females aged 45 years or older, Fitzpatrick phototypes I–VI, with evidence of skin aging. Participants applied ST26-PF-F1 twice daily. Efficacy (expert evaluation, instrumental measurements, confocal microscopy, and participant self-assessments) and tolerability/safety (dermatologist and participant reporting) were assessed at weeks 2, 4, 8, and 12.
Results: Statistically significant improvements from baseline were observed for expert evaluator global assessments of fine lines, skin elasticity and plumpness, and facial contour and facial sagging (all time points); and wrinkles and skin firmness (weeks 4, 8, and 12). Significant improvements were also observed in skin hydration and elasticity (all time points); wrinkle volume, depth, and skin texture (weeks 4, 8, and 12); and lifting effect and V-shape (week 12). Confocal microscopy showed statistically significant improvements in interkeratinocyte brightness, papilla morphology, and dermal collagen fibers at weeks 4 and 12 and surface uniformity and keratinocyte morphology at week 12. Participants reported skin improvements across multiple measures and overall product satisfaction. ST26-PF-F1 was well tolerated with no treatment-related stinging, itching, or discomforting sensations.
Conclusion: Clinical, instrumental, and microscopy assessments of ST26-PF-F1 demonstrated wrinkle-modulating and filler-like effects, visibly more balanced-looking facial geometry, favorable tolerability, and user satisfaction.

INTRODUCTION

Age-related changes in the biomechanical properties of skin are important considerations for aesthetic applications including plastic surgery and dermatology, and the increasing need for effective and tolerable treatments for aging skin is underpinned by shifts in both demographics and medicine. The proportion of the world's population older than 60 years of age is expected to double from 12% to 20% between 2015 and 2050.1 As skin ages, the appearance and overall health status of skin are affected, resulting in fine lines, deep wrinkles, sagging, dryness, and rough or uneven texture.2,3 Furthermore, use of glucagon-like peptide-1 receptor agonists (GLP-1 RA) for weight loss, diabetes, and other indications is associated with undesirable cosmetic effects such as reduced facial volume, facial sagging, wrinkles, and appearance of premature aging ("semaglutide face") that can be addressed by dermatologic treatments.4,5

The dermoepidermal junction contains structural proteins, including various collagen types, laminins, and integrins, that provide structural and functional integrity to the skin.6 Skin anisotropy emerges from the alignment of collagen fibers in the dermis, resulting in directionally dependent biomechanical properties such as skin stiffness.7 Skin aging occurs from thickening of collagen fibrils and disorganization of total collagen content of dermal tissue due to a combination of chronological aging, environmental factors such as sunlight exposure and smoking, and genetic factors.2,3 Whereas younger skin is characterized by three-dimensional and pluridirectional orientation of dermal collagen fibers, collagen fibers in aged skin tend to organize in parallel with the skin surface.8 As skin ages, the appearance and overall health status of skin are affected, resulting in fine lines, deep wrinkles, sagging, dryness, and rough or uneven texture.2,3 Effects on facial skin with GLP-1 RA use include loss of dermal and subcutaneous adipose tissue